Refferences
  1. Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28(suppl 4):iv119-iv142.
  2. Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of immunotherapy for the practitioner. J Clin Oncol 2015;33(18):2092-2099.
  3. Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res 2015;4(5):560-575.
  4. Coleman L, Ko C, Dai F, et al. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. J Am Acad Dermatol 2018;80(4):990-997.
  5. Curry JL, Tetzlaff MT, Nagarajan P, et al. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J Cutan Pathol 2017;44(2):158-176.
  6. Shi VJ, Rodic N, Gettinger S, et al. Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy. JAMA Dermatol 2016;152(10):1128-1136.
  7. Sibaud V, Meyer N, Lamant L, Vigarios E, Mazieres J, Delord JP. Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. Curr Opin Oncol 2016;28(4):254-263.
  8. Sibaud V. Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am J Clin Dermatol 2018;19(3):345-361.
  9. Lomax AJ, McQuillan PA, Hall A, McArthur GA. Acute toxic epidermal necrolysis reaction post single dose pembrolizumab with preceding cephalosporin exposure: successful rechallange with anti-PD-1 therapy. J Intern Med 2019;49:1051-1053.
  10. Vivar KL, Deschaine M, Messina J, et al. Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy. J Cutan Pathol 2017;44:381-384.
  11. Coleman EL, Olamiju B, Leventhal JS. The life-threatening eruptions of immune checkpoint inhibitor therapy. Clinics in Dermatol 2020;38:94-104.
  12. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373(1):23-34.
  13. Suozzi KC, Stahl M, Ko CJ, et al. Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy. JAAD Case Rep 2016;2(3):264-268.
  14. Munoz J, Guillot B, Girard C, Dereure O, Du-Thanh A. First report of ipilimumab induced-Grover disease. Br J Dermatol 2014;171:1236-1237.
  15. Koelzer VH, Buser T, Willi N, et al. Grover’s-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy. J Immunother Cancer 2016;4:47.
  16. Uemura M, Faisal F, Haymaker C, et al. A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-L1. J Immunother Cancer 2016;4:55.
  17. Charollais R, Aubin F, Roche-Kubler B, Puzenat E. Two cases of granuloma annulare under anti-PD1 therapy. Ann Dermatol Venereol 2018;145(2):116-119.
  18. Sheik S, Goddard AL, Luke JJ, et al. Drug-induced dermatomyositis following ipilimumab therapy. JAMA Dermatol 2015;151:195-199.
  19. Yamaguchi Y, Abe R, Haga N, Shimizu H. A case of drug-associated dermatomyositis following ipilimumab therapy. Eur J Dermatol 2016;26:320-326.
  20. Cappeli LC, Gutierrez AK, Baer AN, et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis 2017;76:43-50.
  21. Coleman E, Panse G, Haldas J, Gettinger S, Leventhal JS. Pityriasis rubra pilaris-like erythroderma in the setting of pembrolizumab therapy responsive to acitretin. JAAD Case Rep 2018;4(7):669-671.
  22. Hwang SJE, Carlos G, Wakade D, Sharma R, Fernandez-Penas P. Ipilimumab-induced acute generalized exanthematous pustulosis in a patient with metastatic melanoma. Melanoma Res 2016;26(4):417-420.
  23. Page B, Borradori L, Beltraminelli H, Yawalkar N, Hunger RE. Acute generalized exanthematous pustulosis associated with ipilimumab and nivolumab. J Eur Acad Dermatol Venereol 2018;32(7):e256-e257.
  24. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012;30(21):2691-2697.
  25. Collins LK, Chapman MS, Carter JB, Samie FH. Cutaneous adverse effects of the immunecheckpoint inhibitors. Curr Probl Cancer 2017;41(2):125-128.
  26. Tetzlaff MT, Nagarajan P, Chon S, et al. Lichenoid dermatologic toxicity from immune checkpoint blockade therapy: A detailed examination of the clinicopathologic features. Am J Dermatopathol 2017;39(2):121-129.
  27. Wang LL, Patel G, Chiesa-Fuxench ZC, et al. Timing of onset of adverse cutaneous reactions associated with programmed cell death protein 1 inhibitor therapy. JAMA Dermatol 2018;154(9):1057-1061.
  28. Kato Y, Otsuka A, Miyachi Y, Kabashima K. Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma. J Eur Acad Dermatol Venereol 2016;30(10):e89-e91.
  29. Matsumura N, Ohtsuka M, Kikuchi N, Yamamoto T. Exacerbation of psoriasis during nivolumab therapy for metastatic melanoma. Acta Derm Venereol 2016;96(2):259-260.
Table 1. Demographics, underlying malignancy, and immunotherapy of the trial participants